1-Jul-2026
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
Globe Newswire (Wed, 10-Jun 4:01 PM ET)
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 7-May 4:01 PM ET)
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
Globe Newswire (Thu, 23-Apr 4:01 PM ET)
Market Chameleon (Thu, 30-Oct 6:39 AM ET)
Tectonic Therapeutics Skyrockets 92.5% on Positive Interim Data for TX45
Market Chameleon (Thu, 30-Jan 7:16 AM ET)
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
Tectonic Therapeutic trades on the NASDAQ stock market under the symbol TECX.
As of July 1, 2026, TECX stock price declined to $32.74 with 228,122 million shares trading.
TECX has a beta of 0.03, meaning it tends to be less sensitive to market movements. TECX has a correlation of 0.00 to the broad based SPY ETF.
TECX has a market cap of $617.78 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that TECX belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.
TECX has outperformed the market in the last year with a price return of +62.4% while the SPY ETF gained +22.0%. However, in the short term, TECX had mixed performance relative to the market. It has underperformed in the last 3 months, returning +6.4% vs +14.1% return in SPY. But in the last 2 weeks, TECX shares have fared better than the market returning +8.9% compared to SPY +1.2%.
TECX support price is $32.97 and resistance is $35.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TECX shares will trade within this expected range on the day.